Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BI 695502 + chemotherapy
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**BI 695502 + chemotherapy** refers to the use of the bevacizumab biosimilar candidate BI 695502 in combination with chemotherapeutic regimens for cancer treatment, notably in metastatic colorectal cancer (mCRC) and non–small cell lung cancer (NSCLC). BI 695502 is a biosimilar to the reference product bevacizumab (Avastin) and functions as an anti-angiogenic agent by inhibiting vascular endothelial growth factor A (VEGF-A), thereby preventing tumor blood vessel growth. In clinical studies, BI 695502 has been administered with standard chemotherapy regimens such as mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil) for mCRC and with paclitaxel/carboplatin for NSCLC. Studies have demonstrated safety, tolerability, bioequivalence to bevacizumab, and similar efficacy profiles for the combination in these indications[1][4][5][7][8].
- Other names
- BI 695502 + mFOLFOX6BI 695502 plus chemotherapyBI695502 plus chemotherapyBI-695502 plus chemotherapy
02
Targets
Beyond the preview
Go deeper on BI 695502 + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BI 695502 + chemotherapy.